Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-12-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
独立董事关于第二届董事会第十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting item about the transfer of shares in a subsidiary and related party transactions. It references compliance with stock exchange listing rules and company articles but does not contain financial statements or detailed financial data. The document is a formal board/management related announcement concerning governance and transaction approval. It is not a full annual report, audit report, or financial report. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board opinions, not a report publication or regulatory filing.
2019-12-27 Chinese
关于控股股东部分股份解除质押及重新质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder of Shenzhen BGI Genomics Co., Ltd. It details the number of shares pledged and released, the proportion of shares involved, the financing purpose, and the financial status of the controlling shareholder and its related parties. The document does not contain financial statements or comprehensive financial performance data of the company itself, nor is it a transcript, presentation, or report of earnings or management discussion. It is a regulatory announcement about share pledge activities by major shareholders, which fits the category of Major Shareholding Notification (MRQ).
2019-12-26 Chinese
中信证券股份有限公司关于公司2019年持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2019年持续督导现场检查报告" (2019 Continuous Supervision On-site Inspection Report) issued by CITIC Securities Co., Ltd. regarding Shenzhen BGI Genomics Co., Ltd. It details the on-site inspection findings, governance, internal controls, information disclosure, related party transactions, use of raised funds, performance, and compliance with regulatory requirements for the year 2019. The document includes detailed audit-like findings, corrective measures, and compliance checks, but it is not a full annual report or financial statement. It is a regulatory supervisory inspection report focusing on compliance and governance issues rather than a financial audit report or earnings release. The document is lengthy (over 10,000 characters) and contains substantive content, not just an announcement or certification. Given the nature of the document as a regulatory supervisory inspection report issued by a securities firm and referencing regulatory decisions, it best fits the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. Therefore, the classification is AR with high confidence. FY 2019
2019-12-25 Chinese
2019年第六次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of Shenzhen BGI Genomics Co., Ltd.'s 2019 sixth extraordinary general meeting of shareholders. It details the legal compliance of the meeting's call, attendance, voting procedures, and results. The document does not contain financial statements or management discussion but focuses on the legality and validity of the shareholder meeting and its resolutions. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and related legal opinions on the shareholder meeting.
2019-12-19 Chinese
2019年第六次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2019 sixth extraordinary general meeting of shareholders of Shenzhen BGI Genomics Co., Ltd. It details the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and meeting details. The document length is short (2480 characters) and it serves as an official announcement of voting results from a shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-12-19 Chinese
关于青岛华大基因健康医疗产业园投资进展暨全资子公司签订国有建设用地使用权出让合同的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the progress of investment in a health medical industrial park and the signing of a land use rights transfer contract by its wholly-owned subsidiary. It details the investment amount, land acquisition, contract terms, and the impact on the company. The document is relatively short (2038 characters) and focuses on a specific transaction and investment update rather than providing comprehensive financial data or full financial statements. It does not contain quarterly or annual financial results, audit opinions, or detailed management discussion and analysis. It is not a report but an announcement of a transaction and investment progress. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including significant investment and land acquisition announcements.
2019-12-18 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.